{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T12:30:47Z","timestamp":1754483447807,"version":"3.37.3"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T00:00:00Z","timestamp":1673481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T00:00:00Z","timestamp":1673481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s40744-022-00522-0","type":"journal-article","created":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T07:03:09Z","timestamp":1673506989000},"page":"307-327","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparative Efficacy of Biologic Disease-Modifying Anti-Rheumatic Drugs for Non-Radiographic Axial Spondyloarthritis: A Systematic Literature Review and Bucher Indirect Comparisons"],"prefix":"10.1007","volume":"10","author":[{"given":"Nurullah","family":"Akko\u00e7","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos H.","family":"Arteaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone E.","family":"Auteri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marissa","family":"Betts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyle","family":"Fahrbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mindy","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep","family":"Kiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binod","family":"Neupane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl","family":"Gaffney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip J.","family":"Mease","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,12]]},"reference":[{"key":"522_CR1","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s40744-019-0146-6","volume":"6","author":"PC Robinson","year":"2019","unstructured":"Robinson PC, Sengupta R, Siebert S. Non-radiographic axial spondyloarthritis (nr-axSpA): advances in classification, imaging and therapy. Rheumatol Therapy. 2019;6:165\u201377.","journal-title":"Rheumatol Therapy"},{"key":"522_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-016-1093-z","volume":"18","author":"JJ de Winter","year":"2016","unstructured":"de Winter JJ, van Mens LJ, van der Heijde D, Landew\u00e9 R, Baeten DL. Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis. Arthritis Res Ther. 2016;18:1\u201311.","journal-title":"Arthritis Res Ther"},{"key":"522_CR3","first-page":"2","volume":"2","author":"R van der Meer","year":"2021","unstructured":"van der Meer R, Arends S, Kruidhof S, et al. Extraskeletal manifestations in axial spondyloarthritis are associated with worse clinical outcomes despite the use of tumor necrosis factor inhibitor therapy. J Rheumatol. 2021;2:2.","journal-title":"J Rheumatol"},{"key":"522_CR4","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1007\/s10067-021-05642-6","volume":"40","author":"T Hunter","year":"2021","unstructured":"Hunter T, Sandoval D, Booth N, Holdsworth E, Deodhar A. Comparing symptoms, treatment patterns, and quality of life of ankylosing spondylitis and non-radiographic axial spondyloarthritis patients in the USA: findings from a patient and rheumatologist Survey. Clin Rheumatol. 2021;40:3161\u20137.","journal-title":"Clin Rheumatol"},{"key":"522_CR5","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1002\/acr.23534","volume":"70","author":"PJ Mease","year":"2018","unstructured":"Mease PJ, Heijde DV, Karki C, et al. Characterization of patients with ankylosing spondylitis and nonradiographic axial spondyloarthritis in the US-based corrona registry. Arthritis Care Res (Hoboken). 2018;70:1661\u201370.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"522_CR6","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1002\/acr.21688","volume":"64","author":"U Kiltz","year":"2012","unstructured":"Kiltz U, Baraliakos X, Karakostas P, et al. Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis? Arthritis Care Res (Hoboken). 2012;64:1415\u201322.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"522_CR7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","volume":"390","author":"J Sieper","year":"2017","unstructured":"Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet. 2017;390:73\u201384.","journal-title":"Lancet"},{"key":"522_CR8","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/art.41042","volume":"71","author":"MM Ward","year":"2019","unstructured":"Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology\/Spondylitis Association of America\/spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2019;71:1599\u2013613.","journal-title":"Arthritis Rheumatol"},{"key":"522_CR9","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1136\/ard.2011.151027","volume":"70","author":"J Braun","year":"2011","unstructured":"Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011;70:896\u2013904.","journal-title":"Ann Rheum Dis"},{"key":"522_CR10","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1093\/rheumatology\/kex361","volume":"57","author":"D Poddubnyy","year":"2018","unstructured":"Poddubnyy D, Sieper J. What is the best treatment target in axial spondyloarthritis: tumour necrosis factor \u03b1, interleukin 17, or both? Rheumatology. 2018;57:1145\u201350.","journal-title":"Rheumatology"},{"key":"522_CR11","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1002\/art.40866","volume":"71","author":"A Deodhar","year":"2019","unstructured":"Deodhar A, Gensler LS, Kay J, et al. A fifty-two\u2013week, randomized, placebo-controlled trial of certolizumab pegol in nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2019;71:1101\u201311.","journal-title":"Arthritis Rheumatol"},{"key":"522_CR12","first-page":"2","volume":"2","author":"M Dougados","year":"2014","unstructured":"Dougados M, van der Heijde D, Sieper J, et al. The symptomatic efficacy and effect on objective signs of inflammation of etanercept in early nonradiographic axial spondyloarthritis. Arthritis Rheumatism. 2014;2:2.","journal-title":"Arthritis Rheumatism."},{"key":"522_CR13","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1136\/annrheumdis-2015-eular.1214","volume":"74","author":"J Sieper","year":"2015","unstructured":"Sieper J, Van Der Heijde D, Dougados M, et al. A randomized, double-blind, placebo-controlled, 16-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis. Ann Rheum Dis. 2015;74:283.","journal-title":"Ann Rheum Dis"},{"key":"522_CR14","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1136\/annrheumdis-2012-201766","volume":"72","author":"J Sieper","year":"2013","unstructured":"Sieper J, van der Heijde D, Dougados M, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis. 2013;72:815\u201322.","journal-title":"Ann Rheum Dis"},{"key":"522_CR15","unstructured":"UCB Data on File. AS001 Trial: Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis. 2013."},{"key":"522_CR16","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0140-6736(19)32971-X","volume":"395","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, van der Heijde D, Gensler LS, et al. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. Lancet. 2020;395:53\u201364.","journal-title":"Lancet"},{"key":"522_CR17","doi-asserted-by":"crossref","unstructured":"Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2022.","DOI":"10.1136\/ard-2023-223937"},{"key":"522_CR18","unstructured":"Food and Drug Administration. CIMZIA (certolizumab pegol) for injection, for subcutaneous use https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/125160s283lbl.pdf. Published 2018. Accessed."},{"key":"522_CR19","unstructured":"UCB Canada. CIMZIA\u00ae (certolizumab pegol) Now Approved in Canada for the Treatment of Non-Radiographic Axial Spondyloarthritis. https:\/\/ceo.ca\/@newswire\/cimzia-certolizumab-pegol-now-approved-in-canada. Published 2020. Accessed August 2021."},{"key":"522_CR20","unstructured":"European Medicines Agency. EPAR summary for the public: Cimzia certolizumab pegol. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/cimzia-epar-medicine-overview_en.pdf. Published 2019. Accessed 11 July 2022."},{"key":"522_CR21","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","volume":"73","author":"R Landewe","year":"2014","unstructured":"Landewe R, Braun J, Deodhar A, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis. 2014;73:39\u201347.","journal-title":"Ann Rheum Dis"},{"key":"522_CR22","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1093\/rheumatology\/kex174","volume":"56","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde D, Dougados M, Landewe R, et al. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA. Rheumatology (Oxford). 2017;56:1498\u2013509.","journal-title":"Rheumatology (Oxford)"},{"key":"522_CR23","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"D Van Der Heijde","year":"2017","unstructured":"Van Der Heijde D, Ramiro S, Landew\u00e9 R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76:978\u201391.","journal-title":"Ann Rheum Dis"},{"key":"522_CR24","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s13075-021-02650-4","volume":"23","author":"WP Maksymowych","year":"2021","unstructured":"Maksymowych WP, Kumke T, Auteri SE, Hoepken B, Bauer L, Rudwaleit M. Predictors of long-term clinical response in patients with non-radiographic axial spondyloarthritis receiving certolizumab pegol. Arthritis Res Ther. 2021;23:274.","journal-title":"Arthritis Res Ther"},{"key":"522_CR25","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions. Second Edition 2019.","DOI":"10.1002\/9781119536604"},{"key":"522_CR26","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162:777\u201384.","journal-title":"Ann Intern Med"},{"key":"522_CR27","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:2.","journal-title":"BMJ"},{"key":"522_CR28","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","volume":"50","author":"HC Bucher","year":"1997","unstructured":"Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50:683\u201391.","journal-title":"J Clin Epidemiol"},{"key":"522_CR29","unstructured":"UCB. Data on File. In."},{"key":"522_CR30","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11926-015-0522-3","volume":"17","author":"R Landewe","year":"2015","unstructured":"Landewe R, van Tubergen A. Clinical tools to assess and monitor spondyloarthritis. Curr Rheumatol Rep. 2015;17:47.","journal-title":"Curr Rheumatol Rep"},{"key":"522_CR31","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/1741-7015-11-159","volume":"11","author":"JP Jansen","year":"2013","unstructured":"Jansen JP, Naci H. Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers. BMC Med. 2013;11:159.","journal-title":"BMC Med"},{"key":"522_CR32","doi-asserted-by":"crossref","unstructured":"Viechtbauer W. Conducting meta-analyses in R with the metafor package. 2010. 2010;36:48","DOI":"10.18637\/jss.v036.i03"},{"key":"522_CR33","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1002\/art.23606","volume":"58","author":"H Haibel","year":"2008","unstructured":"Haibel H, Rudwaleit M, Listing J, et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum. 2008;58:1981\u201391.","journal-title":"Arthritis Rheum"},{"key":"522_CR34","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/S0140-6736(18)31362-X","volume":"392","author":"R Landew\u00e9","year":"2018","unstructured":"Landew\u00e9 R, Sieper J, Mease PJ, et al. Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study. Lancet. 2018;392:134\u201344.","journal-title":"Lancet"},{"key":"522_CR35","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1136\/annrheumdis-2020-eular.3472","volume":"79","author":"T Rusman","year":"2020","unstructured":"Rusman T, Van der Weijden MAC, Nurmohamed MT, Landewe R, et al. OP0110: Is very early treatment effective? Six months results of the PREVAS study, a placebo-controlled trial with etanercept in patients suspected of non-radiographic axial spondyloarthritis. Ann Rheum Dis. 2020;79:72\u20133.","journal-title":"Ann Rheum Dis"},{"key":"522_CR36","unstructured":"UCB. AS0006 data on file. In:2018."},{"key":"522_CR37","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/art.41477","volume":"73","author":"A Deodhar","year":"2021","unstructured":"Deodhar A, Blanco R, Dokoupilova E, et al. Improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab: primary results of a randomized placebo-controlled phase III study. Arthritis Rheumatol. 2021;73:110\u201320.","journal-title":"Arthritis Rheumatol"},{"key":"522_CR38","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/ard.2010.133645","volume":"70","author":"M Rudwaleit","year":"2011","unstructured":"Rudwaleit M, van der Heijde D, Landewe R, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70:25\u201331.","journal-title":"Ann Rheum Dis"},{"key":"522_CR39","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1002\/art.11325","volume":"48","author":"JC Davis Jr","year":"2003","unstructured":"Davis JC Jr, Van Der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 2003;48:3230\u20136.","journal-title":"Arthritis Rheum"},{"key":"522_CR40","unstructured":"ClinicalTrials.gov, Pfizer. NCT***01258738: study comparing etanercept (ETN) against a placebo for etanercept on a background nonsteroidal anti inflammatory drug (NSAIDs) in the treatment of early spondyloarthritis (SpA) patients who do not have X-ray structural changes (EMBARK). https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT***01258738?term=NCT**01258738&draw=2&rank=1. Published 2015. Accessed 2021."},{"key":"522_CR41","first-page":"2","volume":"72","author":"S Kiri","year":"2020","unstructured":"Kiri S, Kim M, Betts M, et al. Network meta-analysis of long-term efficacy (ASAS40) of biologic disease-modifying anti-rheumatic drugs (bDMARDs) in bDMARD-Na\u00efve patients with non-radiographic axial spondyloarthritis [abstract]. Arthritis Rheumatol. 2020;72:2.","journal-title":"Arthritis Rheumatol."},{"issue":"1\u2013334","key":"522_CR42","first-page":"5","volume":"20","author":"M Corbett","year":"2016","unstructured":"Corbett M, Soares M, Jhuti G, et al. Tumour necrosis factor-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation. Health Technol Assess. 2016;20(1\u2013334):5\u20136.","journal-title":"Health Technol Assess"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-022-00522-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-022-00522-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-022-00522-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T05:37:36Z","timestamp":1678685856000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-022-00522-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,12]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["522"],"URL":"https:\/\/doi.org\/10.1007\/s40744-022-00522-0","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"type":"print","value":"2198-6576"},{"type":"electronic","value":"2198-6584"}],"subject":[],"published":{"date-parts":[[2023,1,12]]},"assertion":[{"value":"6 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}